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Clinical implication of changes in serum
adiponectin in patients with hepatogenic
diabetes
Zhongying Bao1, Xiaodong Yuan1, Shuhong Duan1 & Xiaoqun Dong2
1Department of Infectious Diseases, Beijing Shijitan Hospital, Capital Medical University (The 9th affiliated hospital of Peking
University), Beijing, 100038, P.R. China, 2Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University
of Rhode Island, Kingston, RI 02881, USA.
Adiponectin is a protein hormone thatmodulates glucosemetabolism and fatty acid oxidation.We explored
the clinical implication of serum adiponectin in hepatogenic diabetes. Serum adiponectin levels were
determined using enzyme–linked immunochemistry assay in 78 individuals including 19 hepatogenic
diabetes, 20 type 2 diabetes (T2D), 20 chronic liver disease and 19 healthy controls. Cases and controls were
matched by gender and body mass index (BMI). There is no difference in serum adiponectin levels among
hepatogenic diabetic, T2D and healthy control groups. The levels of adiponectin are highest in chronic liver
disease and lowest in T2D. Insulin levels are highest in hepatic diabetics and lowest in T2D.Hepatic diabetics
have the lowest insulin sensitivity index (ISI). Serum adiponectin levels were negatively correlated with
triglycerides and total cholesterol in T2D. Serum adiponectin is significantly increased in chronic liver
disease, but lacks association with hepatogenic diabetes.
A
diponectin is an adipocyte-derived hormone encoded byADIPOQ gene. Several genome-wide association
studies have mapped ADIPOQ gene located on chromosome 3q27 as a susceptibility locus for type 2
diabetes (T2D) and metabolic syndrome1. Decreased expression of adiponectin may confer insulin
resistance in murine models of altered insulin sensitivity1. Adiponectin is proposed to reverse insulin resistance
by decreasing triglyceride content in muscle and liver in obese mice1, which results from increased expression of
molecules involved in fatty-acid combustion and energy dissipation inmuscle1–3. In addition, insulin resistance in
lipoatrophic mice was completely reversed by the combination of physiological doses of adiponectin and leptin,
but only partially by either adiponectin or leptin alone1. Thus the replenishment of adiponectin may provide a
novel treatment modality for insulin resistance and T2D1.
Accumulating evidence has shown that adiponectin is involved inmultiple important biological functions such
as regulating glucose transporter, enhancing insulin sensitivity, and attenuating inflammation4. Notably, chronic
hepatitis has been shown to cause changes in adiponectin levels5,6. However, there are very few studies on the
change in adiponectin levels in patients with hepatogenic diabetes. Therefore, we compared the content of the
plasma adiponectin of healthy controls to patients with hepatogenic diabetes, chronic liver disease and T2D. We
tested whether the changes in adiponectin levels correlates with the above-mentioned diseases and evaluated the
value of adiponectin as an early diagnostic marker for hepatogenic diabetes.
Results
The differences in age, waist, body mass index (BMI), serum adiponectin, fasting glucose, fasting insulin, total
cholesterol, triglycerides, and insulin sensitivity index (ISI) were compared among the four groups (Table 1).
Plasma adiponectin levels. A significant difference in plasma adiponectin levels was observed among the four
groups (P , 0.01). Patients with chronic liver disease had the highest, followed by the healthy control and
hepatogenous diabetic group, T2D had the lowest level of adiponectin.
Fasting glucose. There was a significant difference in fasting glucose levels among the four groups (P , 0.01).
Compared to healthy controls or patients with chronic liver disease, T2D and hepatogenous diabetics had
increased fasting glucose levels (P , 0.05).
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Fasting insulin.We found a significant difference in fasting insulin
levels among four groups were (P , 0.01). Higher levels of fasting
insulin were detected in T2D and hepatogenous diabetics than in
healthy controls or chronic liver disease (P, 0.01). T2D patients had
even higher insulin levels than hepatogenic diabetics (P , 0.01).
Triglycerides. T2D had higher triglycerides than other subjects (P,
0.05).
Total cholesterol. T2D showed increased total cholesterol levels
than other subjects (P , 0.01).
Insulin sensitivity Index (ISI). Patients with hepatogenous diabetes
presented significantly decreased ISI compared with other subjects
(P , 0.01).
Correlation of serum adiponectin with other clinical indicators.
Serum adiponectin levels negatively correlated with triglycerides and
total cholesterol levels in all subjects as demonstrated in Table 2.
Compared with healthy control, serum adiponectin levels in T2D
negatively correlated with triglycerides and total cholesterol levels,
but positively correlated with ISI (P, 0.01) as illustrated in Table 3.
Discussion
Recent studies suggest that adiponectin can significantly improve
insulin resistance and enhance peripheral tissue sensitivity to insulin,
whichmay serve as a target of T2D treatment. Hyperinsulinemia and
insulin resistance are the main features of hepatogenic diabetes. The
role of adiponectin in hepatic diabetes is unclear.We are interested in
whether adiponectin is a diagnostic indicator and a potential thera-
peutic target of hepatogenic diabetes. Insulin resistance has been
proposed as one of the most important causes of liver-induced dia-
betes7. A precise method to determine insulin resistance was the
insulin clamp technique; however, the high expense has limited its
clinical application. Thus amendments have been proposed to
improve the minimal model8. Insulin sensitivity index (ISI) may
replace the insulin clamp technique, as an alternative marker to
reflect insulin resistance of hepatogenic diabetes9. Consistently, we
found ISI in hepatogenic diabetics was decreased significantly com-
paring with other groups, suggesting the presence of insulin resist-
ance8. A recent study on rhesus monkeys observed that circulating
concentrations of the adiponectin are decreased in parallel with
reduced insulin sensitivity during the progression to T2D10.
Adiponectin levels were gradually reduced with the development
of insulin resistance. In our study, patients with T2D had relatively
low levels of baseline insulin compared to healthy controls. We sug-
gest that some patients had low levels of insulin due to dysfunction in
secretion or delayed peak at diagnosis.
Hepatogenous diabetes develops in chronic liver disease; espe-
cially liver cirrhosis and sex hormone metabolism disorders, where
estrogen levels are elevated but androgen are relatively low, resulting
in elevated levels of adiponectin. Interestingly, serum adiponectin
levels in mice presented gender dimorphism, where the females
had higher adiponectin than the males11. Adiponectin receptor 1
(AdipoR1) and 2 (AdipoR2) have been implicated in adiponectin
hoist caused by hepatic diabetes12. Human AdipoR1 was expressed
in skeletal muscle and AdipoR2 mainly in the liver. Hepatogenic
diabetics may have reduced expression of AdipoRs and thus elevated
serum adiponectin due to the destruction and dysfunction of liver
cells5,13.
Adiponectin can be produced by human hepatoma HepG2 cells
after treatment with IL-6 or damaged hepatocytes in response to
CCl4-induced injury in mice14. Adiponectin levels were elevated dur-
ing the progression from chronic hepatitis B to liver fibrosis, which
declined in response to antiviral therapy15. Serum adiponectin levels
were significantly increased in liver cirrhosis, associated with the
reaction of active inflammation in chronic liver disease16.
Adiponectin negatively regulates fatty acid oxidation. We found
that the level of triglyceride and total cholesterol were lower in
chronic liver disease and hepatogenic diabetes, but higher in T2D.
We observed increased insulin levels but decreased insulin sensitivity
index in hepatogenic diabetes, which are consistent with a previous
study10. Another study found no association between adiponectin
levels and insulin resistance of varying degrees of liver cirrhosis16.
In our study, serum adiponectin in healthy controls and T2D nega-
tively correlated with BMI, triglycerides and cholesterol, but posi-
tively correlated with insulin sensitivity index.
Hepatogenic diabetics often accompany with varying degrees of
liver inflammation andmetabolic disorders, which led to the changes
in serum adiponectin levels. Although many studies suggest that
decreased serum adiponectin levels closely related with T2D, it
may not serve as a diagnostic marker for hepatogenic diabetes.
Accumulating evidence indicates that dynamic measurements of
adiponectin levels may predict hepatogenous diabetes. Mice feed
Table 1 | Clinical indicator (mean 6 SD) in study population
Groups
Healthy control (n 5 19) Hepatogenic diabetes (n 5 19) Type II diabetes (n 5 20) Chronic liver disease (n 5 20)
Age 48 6 4.5 53 6 8.6 57 6 6.2 51 6 4.1
Waist (WC) 82.9 6 5.12 84.69 6 6.48 86.1 6 7.07 83.28 6 4.34
BMI 21.7 6 3.3 22.7 6 2.6 23.3 6 1.8 22.0 6 1.9
Adiponectin (mg/mL) 7.16 6 3.45 5.56 6 3.04 2.84 6 0.85 10.24 6 6.23*
Glucose (mg/dL) 3.3 6 2.5D 8.8 6 2.4 9.6 6 4.0& 4.2 6 2.0*
Insulin (mIU/mL) 9.8 6 3.1D 15.5 6 4.1 8.2 6 3.1& 10.6 6 4.4*
Triglycerides (mmol/L) 1.22 6 0.29 1.06 6 0.64 2.04 6 0.51& 1.13 6 0.30
Total cholesterol (mmol/L) 3.61 6 0.46 3.32 6 0.85 5.53 6 1.03& 3.28 6 0.88
Insulin sensitivity index 21.66 6 0.14D 22.04 6 0.17 21.83 6 0.24& 21.68 6 0.21*
*P , 0.05, comparison between hepatogenic diabetes and chronic liver disease.
DP , 0.05, comparison between hepatogenic diabetes and healthy control.
&P , 0.05, comparison between hepatogenic diabetes and type 2 diabetes.
Table 2 | Correlation of serum adiponectin with clinical indicators
Triglycerides Total cholesterol Insulin sensitivity index
R values 22.79 21.6 0.032
P values 0.013 0.043 0.78
Table 3 | Correlation of serum adiponectin with other indicators in
healthy controls and type II diabetics
Triglycerides Total cholesterol Insulin sensitivity index
R values 20.485 27.11 0.391
P values 0.001 ,0.001 0.01
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by high-fat and high-sugar diet can lose weight and present reduced
glucose, fatty acids, triglycerides and insulin resistance when treated
with the globular domain of adiponectin17. Additionally, adiponectin
could reduce glucose levels of murine type I diabetes by reducing
hepatic glucose output18. In our study, adiponectin levels were lower
in hepatic diabetics than healthy controls and chronic liver disease.
Hepatogenous diabetes may benefit from exogenous adiponectin.
The limitations of this study include a small sample size and the
absence of other clinical indicators such as tumor necrosis factor.
Our findings need to be expanded in a large patient population. The
metabolic characteristics and mechanisms of serum adiponectin in
hepatic diabetes need further investigation.
Methods
Patient population. A total of 78 male subjects were recruited at Beijing Shijitan
Hospital including 19 cases of hepatogenic diabetes, 20 cases of T2D, 20 cases of
chronic liver disease and 19 healthy controls. Among hepatic diabetics (mean age 53
6 8.6 years, range 42–71 years), 17 cases were hepatitis B virus-related and 2 cases
were hepatitis C virus-related. T2Dpatients were newly diagnosed (mean age 576 6.2
years, range 37–76 years). Among the 20 patients with chronic liver disease (mean age
51 6 4.1 years, range 42–67 years), 17 cases were hepatitis B virus-related and 3 cases
were hepatitis C virus-related. The healthy control group consisted of 19 individuals
(mean age 48 6 4.5 years, range 37–52 years) with normal blood pressure, blood
lipids, blood glucose levels and no previous history of chronic hepatitis. Each subject
had a body mass index (BMI) less than 25 according to the Obesity Guidelines for
Asia-Pacific region. Hypertensive patients were excluded from the study. Informed
consent was obtained from all subjects. This study was approved by the institutional
review board of Beijing Shijitan Hospital Affiliated to Capital Medical University
(The 9th affiliated hospital of Peking University) and was carried out in accordance
with established national and institutional ethical guidelines regarding the
involvement of human subjects and the use of human tissues for research.
Diagnostic, inclusion and exclusion criteria. The diagnosis of T2D is based on the
Diagnosis andClassification ofDiabetesMellitus of AmericanDiabetes Association19.
Diagnosis of chronic viral hepatitis and liver cirrhosis was based on American
Association for the Study of Liver Diseases (AASLD) Practice Guideline in 200420.
The diagnostic criteria for hepatogenic diabetes include8: 1) Chronic liver disease
occurred before the diabetes; 2) The patient’s liver functionwas abnormal; 3) Elevated
glucose was consistent with the deterioration of liver function; 4) Symptoms of
diabetes were mild or absent and without the complications of diabetes; 5) Fasting
plasma glucose$7.0 mmol/L or normal, but the 2-hour postprandial blood glucose
$11.1 mmol/L; oral glucose tolerance test (OGTT) or fasting blood glucose was
normal or mildly elevated but postprandial glucose$11.1 mmol/L; 6) Insulin release
test showed high levels of fasting plasma insulin and postprandial insulin response
delay; C-peptide/insulin ratio was decreased; 7) Patients had no family history of
diabetes. Patients with secondary hyperglycemia caused by the pituitary, adrenal,
pancreas, and thyroid disease were exclude. Patients with glucose metabolism
disorder caused by drugs such as diuretics, corticosteroids, antihypertensive drugs,
and contraceptives were excluded.
Acquisition and processing of specimens. All subjects were fasted for 12–14 hours,
and fasting venous blood 5 ml were collected in the next morning. Specimens were
centrifuged at 3500 r/min for 10 minutes; serum was separated and kept at 280uC.
Determination of adiponectin. Adiponectin was demined using Enzyme–linked
immunochemistry assay (ELISA) according to the manufacturer’s instruction. The
ELISA kit was purchased from Jingmei Biotech Co Ltd. The data was analyzed using
the MRX-automatic production fluorescence microplate reader (Dynex
Technologies, USA).
Measurement of Glucose, triglycerides, and total cholesterol. Concentrations of
blood glucose, triglycerides, and total cholesterol applied Hitachi 7170 automatic
biochemical analyzer.
Determination of fasting insulin. Fasting insulin was measured using
chemiluminescence detection.
ISI (insulin sensitive index). ISI was calculated as the natural logarithm of the
reciprocal of product fasting blood glucose and fasting insulin.
Statistical analysis. Statistical analysis was performed using SPSS software (version
11.5). The measurement data were expressed as mean 6 standard deviation (SD). For
the data with normal distribution, the differences between groups were examined by
pairwise comparisons; otherwise, data with skewed distribution were first transformed
to log-normal distribution. Association between different indicators was evaluated by
Pearson correlation. A P , 0.05 was considered as statistically significant.
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